Page 2 - Active Biotech News Today

The Annual General Meeting of Active Biotech was held on May 19, 2022. Due to the situation resulting from the Corona virus, the Meeting was carried out through postal voting, without any physical attendance.

Lund May 18, 2022 - Active Biotech AB (Nasdaq Stockholm: ACTI) today announced that the U.S. Food and Drug Administration (FDA) has granted tasquinimod Orphan Drug Designation for the treatment of myelofibrosis. "The

Active Biotech's Annual Report 2021 is now available for download at www.activebiotech.com. The Annual Report will only be digitally distributed. Download as PDF Lund, April 28, 2022 Active

Investegate announcements from Active Biotech, Active Biotech strengthens the patent protection for laquinimod in eye disorders

Lund, April 26, 2022, Active Biotech (NASDAQ STOCKHOLM: ACTI) today announced that the European Patent Office (EPO) has issued a decision to grant Active Biotech's patent related to use of laquinimod as

Investegate announcements from Active Biotech, Active Biotech Interim Report Q1 2022

The shareholders of Active Biotech AB (publ) are invited to the Annual General Meeting of shareholders to be held on Thursday, May 19, 2022. Due to the situation resulting from the Corona virus, the Meeting

The number of shares and votes in Active Biotech has changed as a result of allotment of performance shares under the company's incentive program for the company's employees (Plan 2020/2024). Today

Investegate announcements from Active Biotech, Number of shares and votes in Active Biotech

The correction refers to the administrative costs for the period January - December 2021 that due to oversight have been stated too low. The incorrect amount was SEK 14,0 M, the correct amount is SEK 15